With strong ties to Johns Hopkins and an exclusive license from that institution to more than 15 years of research in the field, FASgen, Inc. was formed as a drug development company by four distinguished researchers to create new therapeutic products based on the selective inhibition of fatty acid biosynthesis. Under a sponsored research agreement with the University. FASgen set about designing and synthesizing many compounds that selectively inhibit fatty acid biosynthesis. One group of these compounds appeared to hold great promise for new highly specific therapeutics for cancer; additional compounds were judged to have the potential of specific therapeutics for obesity and related metabolic disorders; and, an additional group of compounds to have the potential of specific therapeutics for TB, including multiple drug resistant TB (MDR-TB) and latent TB infections that affect one third of the worldâs population. FASgen early developed small molecule compounds that the principals indicated were designed to limit the appetite and to boost the metabolic breakdown of excess fat stored in the body. Despite what had offered great promise, the firm appears to have discontinued operations
